Skip to main content
OpenTrials

Clinical trial condition

Urogenital Diseases

Explore clinical trials studying Urogenital Diseases. Study availability and eligibility vary by location and protocol.

40,124 public trials 6,115 recruiting studies
Refine in advanced search Browse all conditions

Urogenital Diseases trial results

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359

Conditions
Autoimmune Diseases, C3G, Complement-mediated Kidney Disease, +13 more
Locations
  • ADARx Clinical Site Doral, Florida, United States
  • ADARx Clinical Site Miami, Florida, United States
  • ADARx Clinical Site Pembroke Pines, Florida, United States
  • ADARx Clinical Site Iowa City, Iowa, United States
View all 38 locations
View Trial Details
Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613

Conditions
Endocrine Gland Neoplasms, Endocrine System Diseases, Endometrial Cancer, +20 more
Locations
  • University of Arkansas Winthrop P. Rockefeller Cancer Institute Little Rock, Arkansas, United States
  • Precision NextGen Oncology & Research Center Beverly Hills, California, United States
  • SCRI at Denver Health Denver, Colorado, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 15 locations
View Trial Details
Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Mount Sinai Cancer Center ( Site 0029) Miami Beach, Florida, United States
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) Orlando, Florida, United States
  • Winship Cancer Institute of Emory University ( Site 0037) Atlanta, Georgia, United States
  • Illinois Cancer Specialists (ICS) ( Site 8009) Arlington Heights, Illinois, United States
View all 161 locations
View Trial Details
Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High-Risk Non-Muscle-Invasive Bladder Cancer, +9 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Arizona Urology Specialty Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Arkansas Urology Little Rock, Arkansas, United States
View all 80 locations
View Trial Details
Recruiting

Polycystic Ovary Syndrome in Type 1 Diabetes

NCT07490964

Conditions
46, XX Disorders of Sex Development, Adnexal Diseases, Adrenogenital Syndrome, +29 more
Locations
  • Department of Endocrinology and Clinical Nutrition, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, Km 9.1, 28034-Madrid (Spain) Madrid, Spain
View Trial Details
Recruiting

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

NCT04683653

Conditions
Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
Locations
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • University of Illinois at Chicago (UIC) Chicago, Illinois, United States
  • University of Chicago Chicago, Illinois, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819

Conditions
Adnexal Diseases, Advanced Solid Tumors, Biliary Tract Diseases, +53 more
Locations
  • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital Birmingham, Alabama, United States
  • City of Hope - Duarte Cancer Center Duarte, California, United States
  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus Fort Myers, Florida, United States
  • Dana-Farber Cancer Institute - Oncology Department Boston, Massachusetts, United States
View all 54 locations
View Trial Details
Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 414 locations
View Trial Details

Related conditions